FOR IMMEDIATE RELEASE
- New regenerative medicine conference set for Hotel Los Tajibos, Santa Cruz de la Sierra, October 23–24
- Event extends ISSCA’s physician education strategy further into Latin America
- Conference reflects continued regional demand for regenerative medicine training
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 126, its regenerative medicine conference in Santa Cruz de la Sierra, Bolivia, taking place October 23–24 at Hotel Los Tajibos.
The Santa Cruz conference extends ISSCA’s Latin American physician education strategy into a market the organization has not previously featured prominently in its conference calendar, complementing its established programming in Argentina, Brazil, and Colombia. The program includes ISSCA’s flagship and peptide-medicine certification tracks.
ISSCA said Bolivia represents continued regional demand for structured regenerative medicine training and reflects the organization’s strategy of expanding physician access market-by-market across Latin America.
“Every new country on ISSCA’s calendar represents physicians who didn’t have easy access to this kind of training before,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Bolivia is the next step in that expansion.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
